ClinConnect ClinConnect Logo
Search / Trial NCT01540461

Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC)

Launched by BRISTOL-MYERS SQUIBB · Feb 27, 2012

Trial Information

Current as of July 23, 2025

Completed

Keywords

Hcc

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.
  • Inclusion Criteria:
  • Subjects with:
  • Confirmed Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC)
  • Not having received prior systemic treatment for advanced HCC
  • Normal or moderately impaired liver function (Child-Pugh Class A or B (CP total score of ≤ 7))
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
  • Exclusion Criteria:
  • Subjects with:
  • Brain metastasis or evidence of leptomeningeal disease
  • History of impaired brain function (encephalopathy) or active heart disease
  • Unmanageable fluid in the abdomen (ascites)
  • Bleeding esophageal or gastric varices within 2 months prior to inclusion

About Bristol Myers Squibb

Bristol-Myers Squibb (BMS) is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. With a robust portfolio of products across multiple therapeutic areas, including oncology, immunology, cardiovascular, and fibrotic diseases, BMS emphasizes cutting-edge research and a commitment to advancing medical science through clinical trials. The company is driven by a mission to provide transformative therapies, leveraging collaboration and scientific expertise to address unmet medical needs and improve patient outcomes worldwide.

Locations

Nanjing, Jiangsu, China

Beijing, Beijing, China

Ha Erbin, Heilongjiang, China

Patients applied

0 patients applied

Trial Officials

Bristol-Myers Squibb

Study Director

Bristol-Myers Squibb

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials